scholarly journals Specialized Cell-Free DNA Blood Collection Tubes Can Be Repurposed for Extracellular Vesicle Isolation: A Pilot Study

2020 ◽  
Vol 18 (5) ◽  
pp. 462-470 ◽  
Author(s):  
Jessica Heatlie ◽  
Vanessa Chang ◽  
Sandra Fitzgerald ◽  
Yohanes Nursalim ◽  
Kate Parker ◽  
...  
2017 ◽  
Vol 19 (5) ◽  
pp. 801-804 ◽  
Author(s):  
Christina Alidousty ◽  
Danielle Brandes ◽  
Carina Heydt ◽  
Svenja Wagener ◽  
Maike Wittersheim ◽  
...  

2020 ◽  
Author(s):  
Joel Desharnais ◽  
Jacob M. Vasquez ◽  
Katya J. Reshatoff ◽  
Quyen Bui ◽  
Han-Mei Chen ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14529-e14529
Author(s):  
Greg Sommer ◽  
Laura Fredriksen ◽  
Gabriella Iacovetti ◽  
Kyungjin Hong ◽  
Ulrich Schaff

e14529 Background: Sample quality is a critical consideration for high fidelity cell-free DNA (cfDNA) testing. Oncological cfDNA tests used for liquid biopsy typically employ specialty blood collection tubes containing chemical preservatives to minimize degradation of samples prior to lab testing. Here we describe a newly developed device, Zero Delay Plasma– a portable centrifuge and disc system designed to immediately isolate cell-free plasma at the point of blood draw – and evaluate its performance against the Streck cfDNA collection tube. Methods: Whole blood was collected, processed, and stored at room temperature for up to 7 days with both the Zero Delay Plasma system and the Streck cfDNA blood collection tube. Sample hemolysis was measured via cell-free hemoglobin. Genomic contamination and cfDNA signal-to-noise were evaluated by qPCR and electrophoresis, comparing signal from target 150-200bp cfDNA to contaminating longer length genomic sequences in the sample. 2 sets of hemolysis experiments, 2 sets of electrophoresis experiments and 4 sets of qPCR experiments were conducted. Results: Plasma processed with the Zero Delay Plasma system yielded ~4X lower hemolysis levels, ~10X lower genomic contamination, and ~20X higher cfDNA signal-to-noise compared to the Streck cfDNA collection tube after 7 days of storage at room temperature. Conclusions: The Zero Delay Plasma system minimizes sample degradation and analytical background signal for cfDNA testing by immediately removing cells and other contaminants at the point of blood collection. Clinical evaluations are in process.


2018 ◽  
Vol 12 (3) ◽  
pp. 1700121 ◽  
Author(s):  
Juhura G. Almazi ◽  
Peter Pockney ◽  
Craig Gedye ◽  
Nathan D. Smith ◽  
Hubert Hondermarck ◽  
...  

2015 ◽  
Vol 61 (6) ◽  
pp. 886-888 ◽  
Author(s):  
Marc G Denis ◽  
Anne-Chantal Knol ◽  
Sandrine Théoleyre ◽  
Audrey Vallée ◽  
Brigitte Dréno

2016 ◽  
Author(s):  
Inga Medina Diaz ◽  
Stefan Holdenrieder ◽  
Annette Nocon ◽  
Makbule Kobilay ◽  
Dirk Skowasch ◽  
...  

2017 ◽  
Author(s):  
Fumitaka Endo ◽  
Takeshi Iwaya ◽  
Takehiro Chiba ◽  
Mizunori Yaegashi ◽  
Kei Sato ◽  
...  

2020 ◽  
Vol 24 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Renee Stokowski ◽  
Karen White ◽  
Coleen Hacker ◽  
Jigna Doshi ◽  
Maximilian Schmid

Epigenetics ◽  
2020 ◽  
pp. 1-11
Author(s):  
Ruben Van Paemel ◽  
Andries De Koker ◽  
Christa Caggiano ◽  
Annelien Morlion ◽  
Pieter Mestdagh ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Marijana Nesic ◽  
Julie S. Bødker ◽  
Simone K. Terp ◽  
Karen Dybkær

DNA released from cells into the peripheral blood is known as cell-free DNA (cfDNA), representing a promising noninvasive source of biomarkers that could be utilized to manage Diffuse Large B-Cell Lymphoma (DLBCL), among other diseases. The procedure for purification and handling of cfDNA is not yet standardized, and various preanalytical variables may affect the yield and analysis of cfDNA, including the purification kits, blood collection tubes, and centrifugation regime. Therefore, we aimed to investigate the impact of these preanalytical variables on the yield of cfDNA by comparing three different purification kits DNeasy Blood & Tissue Kit (Qiagen), QIAamp Circulating Nucleic Acid Kit (Qiagen), and Quick-cfDNA Serum & Plasma Kit (Zymo Research). Two blood collection tubes (BCTs), EDTA-K2 and Cell-Free DNA (Streck), stored at four different time points before plasma was separated and cfDNA purified, were compared, and for EDTA tubes, two centrifugation regimes at 2000 × g and 3000 × g were tested. Additionally, we have tested the utility of long-term archival blood samples from DLBCL patients to detect circulating tumor DNA (ctDNA). We observed a higher cfDNA yield using the QIAamp Circulating Nucleic Acid Kit (Qiagen) purification kit, as well as a higher cfDNA yield when blood samples were collected in EDTA BCTs, with a centrifuge regime at 2000 × g . Moreover, ctDNA detection was feasible from archival plasma samples with a median storage time of nine years.


Sign in / Sign up

Export Citation Format

Share Document